The role of epidermal growth factor receptor mutations and epidermal growth factor receptor-tyrosine kinase inhibitors in the treatment of lung cancer
Journal
Cancers
Journal Volume
3
Journal Issue
2
Pages
2667-2678
Date Issued
2011
Author(s)
Abstract
Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small-cell lung cancer (NSCLC) cases comprise approximately 85% of the lung cancer cases. Before the era of target therapy, platinum-based doublet chemotherapy only led to a median survival of 8-9 months and a one-year survival of 30%-40% in patients with advanced NSCLC. In July 2002, gefitinib, a small-molecule epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), was approved for the treatment of patients with advanced NSCLC in Japan. After the widespread use of gefitinib in the treatment of NSCLC, there have been many new studies regarding the association between the clinical anticancer efficacy of gefitinib and the somatic EGFR mutation status in patients with NSCLC. This article summarizes the role of EGFR mutations in lung cancer and the use of EGFR antagonists in the treatment of lung cancer and its associated adverse effects. ? 2011 by the authors; licensee MDPI, Basel, Switzerland.
SDGs
Other Subjects
afatinib; carboplatin; cetuximab; docetaxel; epidermal growth factor receptor; epidermal growth factor receptor kinase inhibitor; erlotinib; gefitinib; paclitaxel; placebo; platinum complex; advanced cancer; aging; antineoplastic activity; brain metastasis; brain radiation; cancer chemotherapy; cancer combination chemotherapy; cancer radiotherapy; cancer resistance; cancer survival; coughing; diarrhea; drug dose reduction; drug efficacy; drug eruption; drug safety; drug tolerability; dyspnea; gene mutation; human; hypoxemia; interstitial lung disease; interstitial pneumonia; liver function test; liver injury; liver toxicity; lung adenocarcinoma; lung carcinogenesis; lung non small cell cancer; lung toxicity; nucleic acid base substitution; progression free survival; review; side effect; survival time
Type
review